A LinkedIn post from Pear VC highlights that its portfolio company Infinimmune has announced a collaboration with Merck to identify and develop novel antibody therapeutics. The post emphasizes Infinimmune’s strategy of discovering antibodies directly from the human immune system and enhancing them with artificial intelligence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the collaboration is expected to help Infinimmune scale its “human-first discovery engine” and accelerate development of differentiated biologic drugs. For investors following Pear VC, this suggests potential value creation through deeper exposure to pharmaceutical partnerships and validates Infinimmune’s platform approach within the competitive biotech and AI-enabled drug discovery landscape.